Are Long-Acting Injectables the Future of TB Treatment? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
E-Mail
-AGREEMENT ADVANCES EVOLUTION OF SYNTHETIC LUNG SURFACTANTS TO TREAT RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS IN LOW- AND MIDDLE-INCOME COUNTRIES-
LOS ANGELES (March 8, 2021) The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant formulation to be developed for respiratory distress syndrome (RDS) for premature infants in Low- and Middle-Income countries (LMIC). TLI already maintains patents on this invention in the United States, Canada and Europe.
Newborns experiencing RDS must dramatically increase the effort to take each breath, due to lack of adequate, naturally-occurring surfactant production in their lungs. This deficiency of lung surfactant leads to fatigue, episodes of apnea, hypoxia, wasting, and potentially death if untreated. The standard of care is injecting naturally-occurring surfactant, normally animal-deriv
In-licensed candidate may be an effective intervention for premature infants with respiratory distress syndrome
The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant formulation to be developed for respiratory distress syndrome (RDS) for premature infants in Low- and Middle-Income countries (LMIC).
TLI already maintains patents on this invention in the United States, Canada and Europe. Newborns experiencing RDS must dramatically increase the effort to take each breath, due to lack of adequate, naturally-occurring surfactant production in their lungs.
This deficiency of lung surfactant leads to fatigue, episodes of apnea, hypoxia, wasting, and potentially death if untreated. The standard of care is injecting naturally-occurring surfactant, normally animal-derived, into the lungs of preterm babies a definitive treatment that is lifesaving, but i
The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant formulation to be developed for respiratory distress syndrome (RDS) for premature infants in Low- and Middle-Income countries (LMIC).
The Pew Charitable Trusts
In March, nearly 40 individuals from across the country will meet with their legislators to urge Congress to take bipartisan action to prioritize the battle against antibiotic resistance: a looming global health threat that threatens the future of modern medicine. As part of The Pew Charitable Trusts’ Stand Up to Superbugs initiative, this year’s ambassadors include health care professionals, public health officials, scientists, farmers and ranchers, veterinarians, superbug survivors, and people who have lost loved ones to an antibiotic-resistant infection. They will meet virtually with federal agency leaders and members of Congress to share their superbug stories and expertise, and urge increased commitment and momentum to preserve the effectiveness of existing antibiotics and develop urgently needed new ones.